{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:19:22Z","timestamp":1778221162261,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated adverse drug reaction associated with significant morbidity and mortality. While argatroban is guideline-recommended, fondaparinux is increasingly used off-label; however, comparative real-world data remain limited, particularly in critically ill populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the effectiveness and safety of fondaparinux versus argatroban in patients with suspected or confirmed HIT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included adult patients treated with fondaparinux or argatroban for suspected or confirmed HIT. Argatroban was administered as a continuous intravenous infusion with activated partial thromboplastin time (aPTT)-guided titration, whereas fondaparinux was given as fixed subcutaneous dosing. Propensity score matching (1:1) was performed using clinically relevant baseline variables. Outcomes included bleeding, thrombotic events, platelet recovery, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 148 eligible patients, 96 received fondaparinux and 52 argatroban. After propensity score matching, 94 patients (47 per group) were included. Of these, 33 (22.3%) had confirmed HIT based on PF4 ELISA positivity, while 115 (77.7%) were classified as suspected HIT, defined as patients with negative or unavailable PF4 testing but clinical features consistent with HIT, including platelet count dynamics, with a similar distribution between groups. Overall, 28 patients (29.8%) were hemodynamically unstable at anticoagulation initiation. Baseline characteristics were generally well balanced after matching, although serum creatinine remained higher in the argatroban group. No statistically significant differences were observed between fondaparinux and argatroban in major bleeding (4.3% vs. 12.8%; adjusted OR 4.03, 95% CI 0.64\u201325.49), thrombotic events (2.1% vs. 10.6%; adjusted OR 5.07, 95% CI 0.55\u201346.48), or platelet recovery (87.2% vs. 76.6%; adjusted OR 0.36, 95% CI 0.11\u20131.19). ICU mortality was numerically higher in the argatroban group (40.4% vs. 19.1%; adjusted OR 3.02, 95% CI 1.14\u20137.96), whereas in-hospital mortality and length of stay were comparable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fondaparinux demonstrated comparable safety and effectiveness to argatroban in patients with suspected or confirmed HIT. The higher ICU mortality observed in the argatroban group may reflect residual confounding related to illness severity and renal dysfunction. These findings suggest that fondaparinux may be a reasonable alternative in selected patients, while emphasizing individualized anticoagulant selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1794887","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:10Z","timestamp":1778219770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Fondaparinux versus argatroban for the management of suspected or confirmed heparin-induced thrombocytopenia: a propensity score\u2013matched cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lama","family":"Alfehaid","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmaceutical Care, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Sulaiman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmaceutical Care, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]},{"name":"Saudi Critical Care Pharmacy Research (SCAPE) Platform","place":["Riyadh, Saudi Arabia"]},{"name":"Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society)","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulmajeed M.","family":"Alshehri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmaceutical Care, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh","family":"Alyousef","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weam","family":"Abualghaith","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Alsabr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Vishwakarma","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia","place":["Norwich, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Alsuhebany","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmaceutical Care, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman I.","family":"Alshaya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmaceutical Care, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shmeylan","family":"Al Harbi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"Department of Pharmaceutical Care, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"B2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management.","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest."},{"key":"B5","first-page":"3","article-title":"The pharmacotherapy of heparin-induced thrombocytopenia (HIT): a review of contemporary therapeutic challenges in clinical practice.","volume":"15","author":"Hassan","year":"2008","journal-title":"Malays J Med Sci."},{"key":"B6","volume-title":"Arixtra (fondaparinux sodium) injection prescribing information.","year":"2005"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1160\/TH09-01-0008","article-title":"Prescription of fondaparinux in hospitalised patients.","volume":"101","author":"Baroletti","year":"2009","journal-title":"Thromb Haemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1160\/TH07-04-0252","article-title":"Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.","volume":"99","author":"Lobo","year":"2008","journal-title":"Thromb Haemost."},{"key":"B9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1076029609347900","article-title":"Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.","volume":"16","author":"Grouzi","year":"2010","journal-title":"Clin Appl Thromb Hemost."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1111\/j.1538-7836.2011.04487.x","article-title":"Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.","volume":"9","author":"Warkentin","year":"2011","journal-title":"J Thromb Haemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00277-018-3422-6","article-title":"Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia.","volume":"97","author":"Al-Eidan","year":"2018","journal-title":"Ann Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study.","volume":"125","author":"Kang","year":"2015","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ajh.26166","article-title":"Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia.","volume":"96","author":"Nilius","year":"2021","journal-title":"Am J Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","article-title":"Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia.","volume":"70","author":"Schindewolf","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1182\/bloodadvances.2020002963","article-title":"Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.","volume":"4","author":"Morgan","year":"2020","journal-title":"Blood Adv."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1182\/bloodadvances.2024012345","article-title":"Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort.","volume":"9","author":"Nilius","year":"2025","journal-title":"Blood Adv."},{"key":"B17","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in non-surgical patients.","volume":"3","year":"2005","journal-title":"J Thromb Haemost."},{"key":"B19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in surgical patients.","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/01.cir.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0049-3848(03)00030-6","article-title":"Evaluation of the pharmacological properties and clinical results of fondaparinux.","volume":"109","author":"Samama","year":"2003","journal-title":"Thromb Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12236","DOI":"10.1097\/MD.0000000000012236","article-title":"Fondaparinux in a critically ill patient with heparin-induced thrombocytopenia: a case report.","volume":"97","author":"He","year":"2018","journal-title":"Medicine (Baltimore)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ndt\/gfh544","article-title":"Use of fondaparinux in a dialysis patient with symptomatic heparin-induced thrombocytopenia type II.","volume":"20","author":"Haase","year":"2005","journal-title":"Nephrol Dial Transplant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40360-023-00643-4","article-title":"Fondaparinux protocol in renal failure and suspected HIT: a retrospective review.","volume":"24","author":"Ghaziri","year":"2023","journal-title":"BMC Pharmacol Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa031798","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.","volume":"349","author":"B\u00fc,ller","year":"2003","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.transci.2018.10.019","article-title":"An update on evidence based diagnostic and confirmatory testing strategies for heparin induced thrombocytopenia using combined immunological and functional assays.","volume":"57","author":"Amiral","year":"2018","journal-title":"Transfus Apher Sci."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1794887\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:56:11Z","timestamp":1778219771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1794887\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1794887"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1794887","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1794887"}}